First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and ...

BioAtla Inc (BCAB) showcases significant advancements in clinical trials while navigating financial hurdles and seeking strategic partnerships.

Phase 1 dose-escalation study ongoing, dosed first three patients at 300 micrograms; data readout expected mid-2025 with dose expansion data readout anticipated 1H 2026Mecbotamab vedotin (Mec-V; ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without ...

Laryngeal cancer is a serious condition that can impact your ability to speak, swallow and in some cases, breathe. Each year, ...

Early stage diagnosis offers the most favorable prognosis for cancer treatment. Although conventional screening methods ...

Adding pembrolizumab before and after surgery reduced recurrence and improved response in patients with locally advanced head ...

Adding perioperative pembrolizumab to standard care can improve EFS in locally advanced head and neck cancer, data suggest.

head and neck surgical oncologist, Dana-Farber Cancer Institute, Boston, at the American Association for Cancer Research (AACR) Annual Meeting 2025. Pembrolizumab — which already carries ...

First Quarter 2025 Financial Results Collaboration revenue for the three months ended March 31, 2025 increased by $18.6 million as compared to the three months ended March 31, 2024, primarily as a ...